文献速递生殖医学

接受体外受精/卵胞浆内单精子注射治疗的患者导向策略涵盖个体化卵母细胞数量(POSEIDON)低预后患者的临床结局:一项多中心回顾性队列研究

Clinical outcomes in Patient-Oriented Strategies Encompassing Individualized Oocyte Number (POSEIDON) low-prognosis patients receiving in vitro fertilization/intracytoplasmic sperm injection treatment: a multicentered retrospective cohort study.
PubMed 文献 · Fertil Steril · 2025-06-28

该多中心回顾性队列研究纳入中国5个城市2013年1月至2017年12月共100,821例接受体外受精/卵胞浆内单精子注射治疗的女性患者,评估不同POSEIDON组的累积活产率。结果显示,年轻低预后患者通过多个卵巢刺激周期可获得与同龄正常反应者相当的累积活产率,但高龄低预后患者(尤其≥40岁)从额外周期中获益较少。

要点

  • POSEIDON组累积活产率从高到低依次为1b、1a、2b、3、2a、4组。
  • 1a和3组每增加一个周期累积活产率持续增加>5%,1b组达到年轻非POSEIDON患者水平。
  • 2a和2b组在第三周期后达平台,4组在第二周期后更早达平台。

核心结论

  • 年轻的POSEIDON低预后患者通过多个卵巢刺激周期可获得与同龄正常反应者相当的累积活产率。
  • 高龄低预后患者,尤其≥40岁者,从额外周期中获益较少。
  • 重复卵巢刺激不能补偿高龄组卵母细胞数量与质量的下降。

研究设计与样本

  • 多中心回顾性队列研究,纳入中国5个城市(广州、武汉、西安、南京、郑州)2013年1月至2017年12月共100,821例接受体外受精/卵胞浆内单精子注射治疗的女性患者。
  • 主要结局为累积活产率,采用Kaplan-Meier法估计,并通过Cox回归模型分析。

主要发现

  • POSEIDON组累积活产率从高到低依次为1b、1a、2b、3、2a、4组。
  • 1a和3组每增加一个周期累积活产率持续增加>5%,1b组累积活产率达到年轻非POSEIDON患者水平。
  • 2a和2b组累积活产率在第三周期后达平台,4组在第二周期后更早达平台。
  • 按年龄分层显示累积活产率随年龄增长而下降,35-37岁和38-39岁患者每增加一个周期累积活产率显著提高>5%,但≥40岁患者从额外周期中获益较少。

关键数值与推荐

  • POSEIDON组累积活产率排序:1b > 1a > 2b > 3 > 2a > 4。
  • 1a和3组每增加周期累积活产率增加>5%。
  • 2a和2b组第三周期后达平台,4组第二周期后达平台。
  • 35-37岁和38-39岁患者每增加周期累积活产率提高>5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate cumulative live birth rates (CLBRs) across different Patient-Oriented Strategies Encompassing Individualized Oocyte Number (POSEIDON) groups undergoing in vitro fertilization treatment. DESIGN: Multicentered retrospective cohort study. SUBJECT(S): A total of 100,821 female patients undergoing in vitro fertilization/intracytoplasmic sperm injection treatments from January 2013 to December 2017 in 5 cities across China (Guangzhou, Wuhan, Xi'an, Nanjing, and Zhengzhou) were included in this study. EXPOSURE: None. MAIN OUTCOME MEASURE(S): Cumulative live birth rates were the primary outcome, estimated using the Kaplan-Meier method, and analyzed through a Cox regression model. RESULTS: The CLBRs across POSEIDON groups were ranked from high to low as follows: POSEIDON groups 1b, 1a, 2b, 3, 2a, and 4. Notably, the CLBRs in POSEIDON groups 1a and 3 demonstrated a consistent increase of >5% with each added cycle, and the CLBRs in POSEIDON group 1b reached that of young non-POSEIDON patients. The CLBRs in POSEIDON groups 2a and 2b reached a plateau after the third cycle, and POSEIDON group 4 plateaued earlier after the second cycle. Age stratification revealed a clear decline in CLBRs with age, which is increasing. Cumulative live birth rates significantly improved by >5% with each added cycle in patients aged 35-37 and 38-39 years, but those aged ≥40 years benefited less from additional cycles. CONCLUSIONS: Young low-prognosis patients in POSEIDON groups could achieve CLBRs comparable with age-matched normal responders through multiple ovarian stimulation cycles. However, advanced-age low-prognosis patients, particularly those aged ≥40 years, benefited less from additional cycles. Repeated ovarian stimulation did not compensate for reduced oocyte quantity and quality in advanced-age groups. The study underscores the importance of tailored clinical approaches based on age and prognostic factors in fertility treatments.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Zou Y, Wang C, Jin L, et al. Clinical outcomes in Patient-Oriented Strategies Encompassing Individualized Oocyte Number (POSEIDON) low-prognosis patients receiving in vitro fertilization/intracytoplasmic sperm injection treatment: a multicentered retrospective cohort study. Fertil Steril. 2025. PMID: 40588148. doi:10.1016/j.fertnstert.2025.06.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。